Volume3, Issue0 (2020) | undefined

Cancer Drug Resistance

Search Log In

Editor-in-Chief: Godefridus J. Peters

Indexing: ESCI, PMC, Scopus, CAS, CNKI, Dimensions, Lens, Embase,

Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)] Submission to first decision: 10 days

Hot Keywords

ResistanceDrug deliveryNanomedicineTumor microenvironmentImmune checkpoint inhibitorsTarget therapyImmunotherapyRadiotherapyFerroptosisPARP inhibitorsMYCABC transportersAutophagyMetabolismMechanismsPrecision medicineExtracellular vesiclesStem cellBiomarkerOvarian cancerRenal cell carcinomaProstate cancerBreast cancerColorectal cancerMyeloid leukemiaNon-small cell lung cancerPancreatic cancerHead and neck cancerSquamous cell carcinomaMitochondria

Home

About

Publish with us

Articles

Special Issues

Special Collections

Volumes

Pre-onlines

Features

Home Articles Special Issues Volumes Webinars Videos

Cancer Drug Resistance

Editor-in-Chief: Godefridus J. Peters

Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]

Submission to first decision: 10 days

Home Articles Special Issues Volumes Webinars Videos

Home Volumes

Volume

Table of Contents (72 articles)

Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer

William W. Feng, Manabu Kurokawa

Manabu Kurokawa

Pages 1-17

Topoisomerase IB: a relaxing enzyme for stressed DNA

Bini Chhetri Soren, ... Paola Fiorani

Paola Fiorani

Pages 18-25

How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance

Valerio Ciccone, ... Sandra Donnini

Sandra Donnini

Pages 26-37

The importance of epithelial-mesenchymal transition and autophagy in cancer drug resistance

Charlotte Hill

Charlotte Hill

, Yihua Wang

Yihua Wang

Pages 38-47

Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions

Viktorija Juric, Brona Murphy

Pages 48-62

Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients

Heidi Schwarzenbach

Heidi Schwarzenbach

, Peter B. Gahan

Pages 63-82

Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients

Andrea Mayado, ... Leon W.M.M. Terstappen

Pages 83-97

Circulating tumor cells and drug history in primary breast cancer patients

Silvia Jurisova, ... Michal Mego

Pages 98-109

Acknowledgement to reviewers of Cancer Drug Resistance in 2019

Cancer Drug Resistance Editorial Office

Pages 110-112

Epigenetic basis of cancer drug resistance

Moammir H. Aziz, Aamir Ahmad

Aamir Ahmad

Pages 113-116

The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies

Lorena Quirico, Francesca Orso

Francesca Orso

Pages 117-139

Cancer stem cells, plasticity, and drug resistance

Maria Chiara Lionetti, ... Caterina A. M. La Porta

Pages 140-148

The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance

Christophe Lotz, Valérie Lamour

Pages 149-160

Effects of DNA topoisomerase IIα splice variants on acquired drug resistance

Terry S. Elton, ... Jack C. Yalowich

Pages 161-170

Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer

Barbara Rath, ... Gerhard Hamilton

Pages 171-178

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem

Reema Wahdan-Alaswad, ... Ann D. Thor

Pages 179-198

Gene silencing of HIF-2α disrupts glioblastoma stem cell phenotype

Leora M. Nusblat, ... Charles M. Roth

Pages 199-208

Imaging probes for non-invasive tumoral detection and functional monitoring of cancer multidrug resistance

Filipa Mendes, ... António Paulo

Pages 209-224

“Pharmacogenetics of Cancer” - Cancer Drug Resistance special issue

Enrico Mini

Enrico Mini

, Stefania Nobili

Pages 225-231

Cell-mediated immune resistance in cancer

Yuhao Wang, ... Benjamin Bonavida

Pages 232-251

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy

Yu Fujiwara, ... Naoko Takebe

Pages 252-275

Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?

Ivan Pourmir, ... Elizabeth Fabre

Pages 276-286

Drug resistance in glioblastoma: are persisters the key to therapy?

Lisa Oliver

Lisa Oliver

, ... François M. Vallette

Pages 287-301

Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance

Siwei Chu

Siwei Chu

, Ursula Stochaj

Ursula Stochaj

Pages 302-333

Glioblastoma chemoresistance: roles of the mitochondrial melatonergic pathway

George Anderson

George Anderson

Pages 334-355

Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy

Simone Anfossi

Simone Anfossi

, George A. Calin

Pages 356-370

Methods for extracellular vesicle isolation from cancer cells

Israa Salem, ... Lucia R. Languino

Pages 371-384

MicroRNA and liver cancer

Masaya Onishi, ... Yasuhito Tanaka

Pages 385-400

Nitric oxide-elicited resistance to anti-glioblastoma photodynamic therapy

Albert W. Girotti, ... Witold Korytowski

Pages 401-414

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

Thomas E. Lew, ... John F. Seymour

Pages 415-444

Resistance to chemoimmunotherapy in non-small-cell lung cancer

Maximilian Johannes Hochmair

Pages 445-453

Resistance to cancer immunotherapy in metastatic renal cell carcinoma

Marco Moreira, ... Yann-Alexandre Vano

Pages 454-471

RET kinase alterations in targeted cancer therapy

Xuan Liu, ... Jie Wu

Jie Wu

Pages 472-481

Targeting IKKα kinase to prevent tumor progression and therapy resistance

Carlota Colomer, ... Lluís Espinosa

Pages 482-490

The dark side of immunotherapy: pancreatic cancer

Gianluca Mucciolo, ... Paola Cappello

Paola Cappello

Pages 491-520

The role of cell free DNA and liquid biopsies in haematological conditions

Nicholas Bingham, Andrew Spencer

Pages 521-531

Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia

Narjis Fatima, ... Oliver Giles Best

Pages 532-549

Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite

Ajay Gupta, ... Timothy P. Cripe

Pages 550-562

Development of a TCR beta repertoire assay for profiling liquid biopsies from NSCLC donors

Leisa P. Jackson, ... Gary A. Pestano

Pages 563-571

Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma

Aubrey L. Miller, ... Karina J. Yoon

Pages 572-585

Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells

Linda T. Senbanjo, ... Meenakshi A. Chellaiah

Pages 586-602

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression

Derek A. Franklin, ... Justin M. Balko

Pages 603-612

Microfluidic chip enables single-cell measurement for multidrug resistance in triple-negative breast cancer cells

Karan Parekh, ... Paul Chi Hang Li

Pages 613-622

Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma

Alicia Martínez-González

Alicia Martínez-González

, ... Pedro C. Lara

Pages 623-635

Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel

Eiman Mukhtar, ... Paraskevi Giannakakou

Pages 636-646

Reversal of doxorubicin resistance in lung cancer cells by neferine is explained by nuclear factor erythroid-derived 2-like 2 mediated lung resistance protein down regulation

Poornima Paramasivan, ... Viswanadha Vijaya Padma

Pages 647-665

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Thales Paulo Batista, Graziela Zibetti Dal Molin

Pages 666-671

Platinum drug sensitivity and resistance in testicular germ cell tumors: two sides of the same coin

Pasquale Rescigno, ... Giovannella Palmieri

Pages 672-675

Molecular mechanisms of docetaxel resistance in prostate cancer

Yohei Sekino

Yohei Sekino

, Jun Teishima

Pages 676-685

Novel approaches to combat chemoresistance against glioblastomas

Rheal A. Towner, ... Nataliya Smith

Pages 686-698

The tumor microenvironment of pancreatic adenocarcinoma and immune checkpoint inhibitor resistance: a perplex relationship

Irem Sahin, ... Ibrahim Halil Sahin

Pages 699-709

Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interference

Helmut H. Popper

Pages 710-725

Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways

Maristella Bungaro, ... Marcello Tucci

Pages 726-741

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms

Shiv Verma

Shiv Verma

, ... Sanjay Gupta

Sanjay Gupta

Pages 742-761

PHGDH as a mechanism for resistance in metabolically-driven cancers

Richa Rathore, ... Brian A. Van Tine

Brian A. Van Tine

Pages 762-774

Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck cancer treatment

Maria Rita Fabbrizi, Jason L. Parsons

Pages 775-790

Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications

Bao-Jie Zhang, ... Wim J. Quax

Pages 791-803

MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer

Theresa Akoto, ... Sharanjot Saini

Pages 804-818

Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance

Yuriko Saiki, ... Akira Horii

Pages 819-831

Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade

Maria L. Lotsberg, ... Agnete S. T. Engelsen

Pages 832-853

Why nanodiamond carriers manage to overcome drug resistance in cancer

Veronika Benson, Abbas Amini

Pages 854-866

3,3'-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs

Bernhard Biersack

Pages 867-878

Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy

Serkan Yaman, ... Kytai T. Nguyen

Pages 879-911

Intracrine androgen biosynthesis and drug resistance

Trevor M. Penning, ... Stephen Plymate

Pages 912-929

Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance

Islam Hassanin

Islam Hassanin

, Ahmed Elzoghby

Ahmed Elzoghby

Pages 930-946

Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells

Xiao-Jing Yan, ... Ji-Qin Lian

Pages 947-958

Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells

Kevin G. Chen, ... Branimir I. Sikic

Pages 959-979

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer

Kevin J. Lee, ... Natalie R. Gassman

Natalie R. Gassman

Pages 980-991

Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?

Carl Christofer Juhlin

Pages 992-1000

Application of liquid biopsy for prognostic status of cancers and drug response

Dario Marchetti

Pages 1001-1002

Nanotechnological approaches for counteracting multidrug resistance in cancer

Chiara Martinelli

Chiara Martinelli

, Marco Biglietti

Pages 1003-1020

How to win the ovarian cancer stem cell battle: destroying the roots

Akimasa Takahashi, ... Ilana Chefetz

Pages 1021-1033

Actions for 0 selected articles

Cancer Drug Resistance

ISSN 2578-532X (Online)

editorial@cdrjournal.com

Navigation

Follow Us

LinkedIn
Twitter
WeChat

Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

partners@oaepublish.com

Discover Content

Language Editing

Layout & Production

Graphical Abstracts

Video Abstracts

Conference Organizer

Strategic Collaborators

Follow OAE

© 2016-2025 OAE Publishing Inc., except certain content provided by third parties

Privacy Cookies Terms of Service